Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Vitamin E, including its various forms such as delta-tocopherol, has been investigated for its potential role in supporting or slowing the progression of age-related macular degeneration (AMD). The rationale for its use is based on the antioxidant properties of vitamin E, as oxidative stress is considered a contributing factor in the development of AMD. The most significant scientific evidence comes from large randomized controlled trials such as the Age-Related Eye Disease Study (AREDS) and AREDS2. These studies examined the effects of a combination of antioxidants (vitamin C, vitamin E, beta-carotene, zinc, and copper) in individuals at high risk for advanced AMD. The original AREDS formulation used alpha-tocopherol as the vitamin E source, not delta-tocopherol. Results showed a modest reduction in the risk of progression to advanced AMD with this antioxidant combination, but the effect of vitamin E alone, or specifically delta-tocopherol, was not isolated or proven.

There is insufficient direct evidence to support the use of delta-tocopherol specifically for AMD. Most studies have focused on alpha-tocopherol, and the overall benefit of vitamin E alone is not strongly supported by clinical trials. Therefore, while antioxidant supplementation (including vitamin E) is part of a validated approach to slowing AMD progression in certain patients, the evidence supporting delta-tocopherol itself is limited, and the benefit of vitamin E alone is modest at best.

More about Vitamin E (delta-tocopherol)
More about Macular Degeneration

Other ingredients used for Macular Degeneration

Other health conditions supported by Vitamin E (delta-tocopherol)

Products containing Vitamin E (delta-tocopherol)